【摘 要】
：
Nail involvement is common in psoriasis and is considered a risk factor for and a predictor of the development of psoriatic arthritis. The treatment of nail psoriasis is challenging because of the unique anatomical structure of nails and the absence of st
【机 构】
：
Department of Physical Therapy, Hospital for Skin Diseases (Institute of Dermatology), Chinese Acade
论文部分内容阅读
Nail involvement is common in psoriasis and is considered a risk factor for and a predictor of the development of psoriatic arthritis. The treatment of nail psoriasis is challenging because of the unique anatomical structure of nails and the absence of standardized treatment protocols. Herein, we provide an up-to-date overview of the treatment options for nail psoriasis, including topical drugs and penetration enhancement strategies, traditional and novel oral drugs, and biologic agents. In addition, we highlight the available individualized management strategies in special patient populations such as pediatric patients, geriatric patients, women of childbearing age, and patients with concomitant onychomycosis or psoriatic arthritis.“,”Nail involvement is common in psoriasis and is considered a risk factor for and a predictor of the development of psoriatic arthritis. The treatment of nail psoriasis is challenging because of the unique anatomical structure of nails and the absence of standardized treatment protocols. Herein, we provide an up-to-date overview of the treatment options for nail psoriasis, including topical drugs and penetration enhancement strategies, traditional and novel oral drugs, and biologic agents. In addition, we highlight the available individualized management strategies in special patient populations such as pediatric patients, geriatric patients, women of childbearing age, and patients with concomitant onychomycosis or psoriatic arthritis.
其他文献
遗传性出血性毛细血管扩张症(hereditary hemorrhagic telangiectasia,HHT)是一种常染色体显性遗传病,患病率约为1/5000,其特征是多发的血管畸形(vascular malformations,VMs).VMs可导致急性和慢性大量出血、动静脉畸形等并发症.2009年首版HHT诊断和治疗国际指南发布,为HHT的诊断、并发症的预防、症状的治疗建立循证共识和指南.第2版指南由来自15个国家的55位专家针对6个优先主题领域(鼻出血、胃肠道出血、贫血和缺铁、肝脏VMs、儿科管理
变应性鼻炎是由人体吸入变应原后出现与阻力血管收缩、容量血管扩张、毛细血管通透性增高等由多种效应细胞浸润引起的一系列有关症状的疾病.变应原特异性免疫治疗是目前唯一有可能通过免疫调节机制改变变应性疾病自然进程的对因治疗方式,通过调查研究变应性鼻炎患者经过特异性免疫治疗后生存质量的变化,对分析特异性免疫治疗的疗效及治疗方案的制定有着重要的意义.
腭、肺及鼻咽上皮克隆(palate,lung and nasal epithelium clone,PLUNC)蛋白具有保守的基因结构,特异性的上皮表达,与杀菌渗透增强蛋白/结合脂蛋白相似的三维结构,被认为是在宿主防御中发挥功能的一类蛋白家族,参与了慢性鼻-鼻窦炎及鼻息肉、变应性鼻炎、支气管哮喘等多种气道变态反应性疾病的发生发展,探索其可能的机制,为寻找精准治疗方案提供生物学基础.
目的 分析遗传性出血性毛细血管扩张症(hereditary hemorrhagic telangiectasia,HHT)患者的临床症状和基因突变,探讨基因检测和遗传咨询对疾病诊断和预防中的应用.方法 收集2例HHT患者的病例资料及外周血样本,应用PCR扩增-测序方法对该病相关的ENG、ACVRL1、SMAD4和BMP9基因全部编码区进行序列分析.结果2例HHT病例均具有反复的鼻出血、皮肤黏膜毛细血管扩张.F1病例具有家族史,F2病例具有肺动脉高压,鼻出血严重程度分析发现年龄大的F2病例较F1病例鼻出血严
目的:探究宫颈鳞癌组织中miR-let-7b、IMP3及HMGA2的表达情况,并探讨其相关性以及临床意义.方法:选取2016年1月至2020年7月徐州市中心医院的207例宫颈组织标本为研究对象,其中包括正常宫颈(normal cervix,NC)30例、低度鳞状上皮内病变(low-grade squamous intraepithelial lesion,LSIL)32例、高度鳞状上皮内病变(high-grade squamous intraepithelial lesion,HSIL)39例、宫颈鳞癌(
目的:探讨卵巢Brenner肿瘤的临床病理特征、免疫表型、诊断及鉴别诊断.方法:回顾性分析21例卵巢Brenner肿瘤的临床资料、组织学形态、免疫表型,并复习相关文献.结果:21例卵巢Brenner肿瘤患者均为成年女性,年龄为28～76(平均52)岁,其中13例(61.9％)已绝经,8例(38.1％)未绝经.囊实性肿物16例,实性肿物5例.经病理诊断为Brenner瘤的有18例(85.7％)、交界性Brenner瘤2例(9.5％),恶性Brenner肿瘤1例(4.7％).常用的肿瘤标志物CA199、CA1
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T-cell lymphoma caused by the human T lymphotropic virus type-1. The skin is affected in approximately half of ATLL patients, and skin lesions may be the first manifestation of the disease.
目的:检测卵巢癌组织中纤维母细胞活化蛋白-α(fibroblast activation proteinα,FAP-α)和血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达情况,探讨其与卵巢癌侵袭和转移的关系.方法:应用免疫组织化学法检测80例卵巢癌组织和30例正常卵巢组织中FAP-α和VEGF的表达,并分析两者的相关性,探讨其与卵巢癌临床病理特征的关系.结果:卵巢癌组织中的FA P-α和VEGF均显著高于正常卵巢组织(P<0.05);在卵巢癌中FAP
目的:基于TCGA和GTEx数据库探讨人免疫球蛋白γ-1重链恒定区(immunoglobulinγ-1 heavy chain constant region,IGHG1)基因在皮肤黑色素瘤中的表达及其临床价值.方法:应用Wilcox检验和logistic回归分析IGHG1与临床病理特征之间的关系.应用Cox回归和Kaplan-Meier法分析皮肤黑色素瘤患者的临床病理特征与总生存率的关系.使用基因集富集分析(gene set enrichment analysis,GSEA)探索IGHG1基因在皮肤黑色
目的:探讨安罗替尼三线及以上治疗晚期非小细胞肺癌的疗效及安全性.方法:收集2018年10月至2020年4月安徽医科大学第一附属医院收治的接受安罗替尼三线及以上治疗的晚期非小细胞肺癌患者25例,通过回顾性分析其临床资料及随访,观察安罗替尼的近期疗效、生存情况、不良反应及预后因素.结果:安罗替尼治疗晚期非小细胞肺癌的客观缓解率(objective response rate,ORR)为12％(3/25),疾病控制率(disease control rate,DCR)为80％(20/25);25例患者的中位无进